


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicants : Seong Hwan CHO et al.

Group Art Unit : 1625

Appl. No. : 10/628,209

Examiner : Patricia L. MORRIS

Filed : July 29, 2003

Confirmation No. : 5477

For : ORGANIC ACID SALT OF AMLODIPINE

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office
220 20th Street S.
Customer Window, Mail Stop _____
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir :

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98 and supplemental to the Information Disclosure Statement that was filed on October 28, 2003, Applicants hereby submit a copy of the following documents:

A copy of an International Search Report that was mailed on October 21, 2003, with respect to patent family member International Patent Application No. PCT/KR03/001523 is attached hereto, in which the following documents were cited:

- (1) European Patent Application Publication No. EP 0 244 944, which was published on March 31, 1987;
- (2) U.S. Patent No. 4,572,909 to CAMPBELL et al., which issued on February 25, 1986;
- (3) U.S. Patent No. 6,057,344 to YOUNG, which issued on May 2, 2000;

(4) U.S. Patent No. 4,806,557 to CAMPBELL et al., which issued on February 21, 1989;

(5) Korean Patent Application Publication No. 1020020076561, which was published on October 11, 2002, together with an English language Abstract of the same;

The category of relevance, pertinent portions, and claims to which each document is relevant, as ascertained by the Korean Examiner applying Korean rules to the Korean claims are set forth in the International Search Report.

Applicants also bring the following documents to the Examiner's attention:

(6) U.S. Patent Application Publication No. 2002/0086888 to BENNEKER et al., which was published on July 4, 2002;

(7) International Patent Application Publication No. WO 02/053538, which was published on July 11, 2002;

Further to the U.S. Patent and Trademark Office's decision to waive the requirement under 37 C.F.R. §1.98 (a)(2)(i), copies of U.S. patents and U.S. patent application publications, which are documents (2)-(4), and (6) are not enclosed herewith. However, if any copies are needed, the Examiner is respectfully requested to contact the undersigned.

Applicants also note that U.S. Patent Application No. 10/628,210, which was previously cited in an Information Disclosure Statement filed in the present application issued as U.S. Patent No. 6,756,390 on June 29, 2004.


Applicants respectfully request that the Examiner consider the above material and cite the same. Copies of the documents (1), (5), and (7) are attached hereto and all of the documents have been listed on the attached PTO-1449 Form. The Examiner is requested

to initial the appropriate spaces on the attached Form and to return a copy of the completed Form to the Applicants with the next official communication in the present application.

Applicants note that a Request for Continued Examination is being submitted herewith, and thus no fee is required to ensure consideration of the submitted material. However, if an Office Action on the merits has issued and is crossing this statement in the mail, the undersigned hereby authorizes the Commissioner to charge any fee necessary for the consideration of this statement, including any payment under 37 C.F.R. §1.17 (p) to Deposit Account No. 19-0089.

Should the Examiner have any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully Submitted,
Seong Hwan CHO et al.


Bruce H. Bernstein
Reg. No. 29,027


Reg. No. 33,094
Annex Tux

August 10, 2004
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Application No.
10/628,209

(Use several sheets if necessary)

Group
1625

[illegible][illegible][illegible]

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.